Quarterly report pursuant to Section 13 or 15(d)

Earnings (Loss) Per Common Share

v3.19.3
Earnings (Loss) Per Common Share
3 Months Ended
Sep. 30, 2019
Earnings (Loss) Per Common Share  
Earnings (Loss) Per Common Share

11.   Earnings (Loss) Per Common Share

Basic earnings (loss) per common share is computed by dividing the net income (loss) allocated to common stockholders by the weighted-average number of shares of common stock outstanding during the period. For purposes of calculating diluted earnings (loss) per common share, the denominator includes both the weighted-average number of shares of common stock outstanding during the period and the number of common stock equivalents if the inclusion of such common stock equivalents is dilutive. Dilutive common stock equivalents potentially include stock options and warrants using the treasury stock method. The following table summarizes the components of the earnings (loss) per common share calculation (in thousands, except per share amounts):

 

 

 

 

 

 

 

 

 

 

Three Months ended

 

 

September 30, 

 

    

2019

    

2018

Basic and diluted numerator:

 

 

  

 

 

  

 

 

 

  

 

 

  

Net loss attributable to iBio, Inc. stockholders

 

$

(4,463)

 

$

(4,398)

  Preferred stock dividends

 

 

(66)

 

 

(66)

Net loss available to iBio, Inc. stockholders

 

$

(4,529)

 

$

(4,464)

 

 

 

  

 

 

  

Basic and diluted denominator:

 

 

  

 

 

  

 

 

 

  

 

 

 

Weighted-average common shares outstanding

 

 

21,923

 

 

17,894

 

 

 

  

 

 

  

Per share amount

 

$

(0.21)

 

$

(0.25)

 

In Fiscal 2020 and Fiscal 2019, the Company incurred net losses which cannot be diluted; therefore, basic and diluted loss per common share is the same. As of September 30, 2019 and 2018, shares issuable which could potentially dilute future earnings were as follows:

 

 

 

 

 

 

 

 

Three Months Ended

 

 

September 30, 

 

    

2019

    

2018

 

 

(in thousands)

Stock options

 

1,347

 

1,364

Series A Preferred

 

430

 

6,103

Series B Preferred

 

6,428

 

6,428

Shares excluded from the calculation of diluted loss per share

 

8,205

 

13,895